Which phase of therapy requires periodic monitoring of ejection fraction?

Monitoring of ejection fraction is a crucial component of cardiac assessment in patients undergoing certain types of cancer therapies, particularly those that use anthracyclines, trastuzumab, or other agents known to impact cardiac function.

Before therapy, evaluating the ejection fraction helps establish a baseline for the patient's heart function, allowing for early identification of any pre-existing issues. During therapy, periodic monitoring is essential due to the potential for cardiac toxicity that may develop as treatment progresses. By assessing ejection fraction at this stage, healthcare providers can intervene promptly if any deterioration in cardiac function is observed. After therapy, continued monitoring is also important, as some cardiac side effects may not become apparent until after treatment has concluded.

This comprehensive monitoring approach aligns with best practices to safeguard against long-term cardiotoxicity, demonstrating the need for a thorough evaluation at multiple points throughout the patient's treatment journey. Hence, the requirement for monitoring ejection fraction extends to before, during, and after therapy.